Medication info
Rosuvastatin 20 mg Tablets (Rosuvastatin Calcium)

Rosuvastatin 20 mg Tablets (Rosuvastatin Calcium)

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium›20.8mg / 1 tablet
Manufacturer / importer
Jinyang Pharmaceutical Co., Ltd.
Appearance
Pink round film-coated tablet
Packaging
28 tablets (14 tablets x 2 PTP), 30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 201000993 · Notified 2010.01.28 · Insurance code 650302680

Summary

Main use
Treatment of dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular disease
Who takes it
Adults · Children
Adult dose
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), combined hyperlipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 mg once daily, which is sufficient to control the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer, according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 mg daily. 3. Elderly patients : No dose adjustment is necessary. 4. Patients with renal impairment : No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20 mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment : No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration in patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race : Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 7. Patients predisposed to myopathy : The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of this medicine is contraindicated in some of these patients.
Child dose
2. Pediatric patients with heterozygous familial hypercholesterolemia (ages 10 to 17 years): The usual dose range is 5 mg to 20 mg once daily. (There are no clinical data on doses greater than 20 mg in pediatric patients.) The dose should be adjusted individually according to the recommended treatment goal for each patient. Dose adjustments should be made at intervals of 4 weeks or longer. Safety and efficacy in children under 10 years of age have not been established.

Ingredients

Manufacturer
Jinyang Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular disease

  • Hypercholesterolemia
  • familial hypercholesterolemia
  • mixed dyslipidemia
  • atherosclerosis
  • dysbetalipoproteinemia
  • cardiovascular disease risk factors
  • stroke risk
  • myocardial infarction risk
  • vascular revascularization risk
View approved original text

This medication is used as an adjunct when diet and exercise are insufficient for controlling primary hypercholesterolemia and heterozygous familial hypercholesterolemia, as well as for patients with mixed dyslipidemia. It is also used in treatment of homozygous familial hypercholesterolemia in combination with other lipid-lowering therapies, and it helps reduce total cholesterol and LDL cholesterol in patients with hypercholesterolemia, thereby delaying the progression of atherosclerosis. It is particularly effective as an adjunct to dietary therapy in pediatric patients aged 10 to 17 years who have heterozygous familial hypercholesterolemia. It also aids in the treatment of patients with type III dysbetalipoproteinemia and contributes to reducing the risk of stroke, myocardial infarction, and vascular revascularization in elderly patients at high risk for cardiovascular disease. Overall, this medication is used for various types of dyslipidemia and reducing the risk of cardiovascular diseases.

How to take

Adult dose

1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), combined hyperlipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 mg once daily, which is sufficient to control the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer, according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 mg daily. 3. Elderly patients : No dose adjustment is necessary. 4. Patients with renal impairment : No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20 mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment : No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration in patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race : Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 7. Patients predisposed to myopathy : The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of this medicine is contraindicated in some of these patients.

Child dose

2. Pediatric patients with heterozygous familial hypercholesterolemia (ages 10 to 17 years): The usual dose range is 5 mg to 20 mg once daily. (There are no clinical data on doses greater than 20 mg in pediatric patients.) The dose should be adjusted individually according to the recommended treatment goal for each patient. Dose adjustments should be made at intervals of 4 weeks or longer. Safety and efficacy in children under 10 years of age have not been established.

Precautions

This medication should not be used in certain patients. First, it must not be administered to individuals allergic to its components or those with severely impaired liver function. Additionally, caution is warranted in individuals with muscle diseases or those taking certain immunosuppressants. Patients with very poor kidney function, pregnant or nursing women, and women of childbearing age who do not use adequate contraception should also avoid this medication. Particularly, patients susceptible to muscle disease should avoid high doses, and those with genetic metabolic disorders like lactose intolerance should not take this medication. Before taking the medication, patients should undergo regular liver function tests and muscle-related tests, and those with a history of significant alcohol consumption or liver disease should exercise additional caution. During treatment, if symptoms like muscle pain, weakness, fatigue, or fever occur, the physician should be notified immediately, and in severe cases, discontinuation of the medication may be required. Also, if an acute severe illness occurs or symptoms of muscle weakness appear, the administration should be stopped. This medication may interact with other drugs, so patients should inform healthcare professionals of any other medications they are taking. Particularly, when taken with certain antiviral drugs, immunosuppressants, antibiotics, or fibrates, the risk of muscle-related adverse effects may increase. Pregnant or nursing women should not take this medication, and women who may become pregnant should ensure appropriate contraception. There is no specific antidote for overdose, so management should be based on symptoms, and monitoring of liver function and muscle enzyme tests should be performed. Finally, this medication may cause side effects like dizziness, so caution is advised when driving or operating machinery. Patients should be well-informed of these precautions when taking this medication and consult healthcare professionals immediately if they experience any unusual symptoms.

Side effects

Hypersensitivity reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, itching, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, myasthenia gravis, cough, dyspnea, diarrhea, ocular muscle weakness, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lichenoid drug eruption, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive decline, forgetfulness, amnesic syndrome, memory impairment, confusion, increased ALT, chest pain, muscle cramps, gout, erectile dysfunction, numbness, sensory disturbances, chest discomfort, decreased appetite, abdominal distension, syncope, generalized pain, fatigue

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container, protected from air and moisture, at room temperature between 1 and 30 degrees Celsius. Proper storage helps maintain the medication's effectiveness over time.

Appearance and packaging

Appearance

Pink round film-coated tablet

Package unit

28 tablets (14 tablets x 2 PTP), 30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.